Resources
BeiGene Medical Europe

Biomarker identification in relapsed/refractory non-germinal center B-cell-like diffuse large B-cell lymphoma treated with Zanubrutinib

 Back View
Biomarker identification in relapsed/refractory non-germinal center B-cell-like diffuse large B-cell lymphoma treated with Zanubrutinib
 POSTER   06/2020
 View

For more information about this resource, please submit a medical information request.

Rating

Rate this resource

Related resources

EHA 2020 & Library: selected abstracts on BeiGene products
EHA 2020 & Library: selected abstracts on BeiGene products
Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: results from a phase 2, single-arm, multicenter, study
Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: results from a phase 2, single-arm, multicenter, study
ASPEN: Results of a Phase 3 Randomized Trial of Zanubrutinib versus Ibrutinib for Patients with Waldenström Macroglobulinemia (EHA)
ASPEN: Results of a Phase 3 Randomized Trial of Zanubrutinib versus Ibrutinib for Patients with Waldenström Macroglobulinemia (EHA)
 Back

Nice to see you!

For newest details on our ESMO materials in a personal video meeting, please click here!
Service